Labiotech.eu

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

biotech portugal vesalius biocapital fund

News and Trends 20 Sep 2017

Biotech in Portugal gets a Boost with New Investment Fund

Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […]

September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […]

September 20, 2017 - 2 minutesmins - By Alex Dale

What you need to Know about the Legalization of Cannabis for Medical Use

It is mentioned in song texts, studied in scientific papers, listed on political agendas: Cannabis. The global discussion has been raging for decades. Should a drug that is listed as a strong narcotic in many countries be legalized for medicinal or recreational use? In recent years, several countries, including Canada, Italy and the Czech Republic […]

September 20, 2017 - 8 minutesmins - By External Contributor

derek jones babraham bioscience technologies incubator

Interview 20 Sep 2017

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […]

September 20, 2017 - 9 minutesmins - By Evelyn Warner

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

More News! 18 Sep 2017

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […]

September 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]

September 18, 2017 - 1 minutemin - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Inside Labiotech 18 Sep 2017

Press Release: We raised our second financing round to become the largest biotech media 🚀

Happy news to announce this morning: we just closed our second fundraising from new and existing investors 😉👌 It’s a major milestone for the development of Labiotech.eu as it will allow us to continue investing in amazing content, launch new products and grow our revenues. Thanks to the team for their amazing work and for making […]

September 18, 2017 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

Biotech in Portugal gets a Boost with New Investment Fund

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

What you need to Know about the Legalization of Cannabis for Medical Use

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Press Release: We raised our second financing round to become the largest biotech media 🚀

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!